DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2227123/sage-therapeutics-sage-q4-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2227123 Feb 15, 2024 - Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise. 0

https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390 Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings. 0

https://www.fool.com/earnings/call-transcripts/2024/02/13/biogen-biib-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Feb 13, 2024 - BIIB earnings call for the period ending December 31, 2023. 0

https://www.zacks.com/stock/news/2225441/here-s-what-key-metrics-tell-us-about-biogen-inc-biib-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2225441 Feb 13, 2024 - The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2224200/ionis-ions-eplontersen-gets-fast-track-tag-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2224200 Feb 09, 2024 - The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). 0

https://www.zacks.com/stock/news/2223511/can-biogen-biib-keep-the-beat-streak-alive-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2223511 Feb 08, 2024 - Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen. 0

https://www.zacks.com/stock/news/2221865/biogen-inc-biib-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2221865 Feb 06, 2024 - Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2217370/will-biogen-inc-biib-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2217370 Jan 29, 2024 - Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. 0

https://www.zacks.com/stock/news/2214591/biogen-inc-biib-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2214591 Jan 23, 2024 - Biogen Inc. (BIIB) closed the most recent trading day at $251.68, moving +1.36% from the previous trading session. 0

https://www.zacks.com/stock/news/2203359/biogen-inc-biib-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2203359 Dec 28, 2023 - The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close. 0